



## FOR IMMEDIATE RELEASE

### PRANA'S CO-FOUNDING SCIENTISTS TO PRESENT AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE ON PREVENTION OF DEMENTIA 2005

Washington, DC - June 20, 2005 - Prana Biotechnology Limited (NASDAQ: PRAN; ASX: PBT), announced today that its co-founding scientists, Drs. Ashley Bush, MD PhD of Massachusetts General Hospital and the Mental Health Research Institute of Victoria (Australia); and Rudolph Tanzi, PhD of Harvard Medical School and Massachusetts General Hospital are scheduled to co-chair and present at the **Alzheimer's Association International Conference on Prevention of Dementia 2005**. Both doctors will reside as co-chairmen at separate sessions for the pre-conference meeting on June 18 called "Clinical Trials Test the "Amyloid Hypothesis": A tutorial on Current Approaches and its Mechanisms. The Conference will be held at the Marriott Wardman Park Hotel, Washington DC.

Scientists from around the world will present and discuss the findings of hundreds of studies showcasing the newest advances and steps toward prevention of Alzheimer's disease and related disorders. At the pre-conference, Dr. Tanzi will co-chair the morning session on 'Brain Amyloid-beta Peptide Oligomers as Therapeutic Targets.' This assembly will discuss the potential of amyloid accumulation in the brain in Alzheimer's' disease as a new drug target. In addition, Dr. Tanzi will share his view about the genetic basis for amyloid accumulation in Alzheimer's disease in a lecture called 'Genetic basis of Cerebral Amyloidosis.'

In the afternoon session, Dr. Bush will co-chair a discussion on the anti-amyloid drug development that does not directly target amyloid, but the chemistry that interacts with the amyloid (metals) called, 'Anti-amyloid Strategies with Complex Targets.' Dr. Bush also intends to present a lecture entitled 'Antagonists of Metal-dependent Oxidation and Protein Interactions' that will focus on the interaction between metals and the protein beta-amyloid, which leads to the toxicity and accumulation.

These insights are the basis of the development of Prana's library of MPAC's (metal protein attenuating compounds), which target neurodegenerative diseases. PBT2, Prana's lead MPAC drug candidate for the potential treatment of Alzheimer's disease is currently in Phase 1 clinical development.

At the conference, nearly 1,000 clinicians, physicians, researchers and policy advocates will explore how science and technology intersect to open new doors for Alzheimer research and care.

## **About Prana Biotechnology Limited**

Prana Biotechnology was established to commercialise research into Alzheimer's disease and other major age-related degenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000. Researchers at prominent international institutions including the University of Melbourne and Massachusetts General Hospital at Harvard Medical School discovered Prana's technology.

This press release contains "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Company's business strategy and future plans of operation. Forward-looking statements involve known and unknown risks and uncertainties; both general and specific to the matters discussed in this press release. These and other important factors, including those mentioned in various Securities and Exchange Commission filings made by the Company, may cause the Company's actual results and performance to differ materially from the future results and performance expressed in or implied by such forward-looking statements. The forward-looking statements contained in this press release speak only as of the date hereof and the Company expressly disclaims any obligation to provide public updates, revisions or amendments to any forward-looking statements made herein to reflect changes in the Company's expectations or future events.

**For further information, please visit our web site at [www.pranabio.com](http://www.pranabio.com).**

### **Investor and media relations**

Rebecca Piercy  
Buchan Consulting  
Ph: 03 9866 4722